These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 17645714

  • 1. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
    Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, Lake J.
    Clin Transplant; 2007; 21(4):526-31. PubMed ID: 17645714
    [Abstract] [Full Text] [Related]

  • 2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 3. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ.
    Clin Transplant; 2007 Aug; 21(1):101-9. PubMed ID: 17302598
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J.
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O, Sahney S, Cutler D, Baron PW, Abdelhalim FM, James S, Zuppan C, Franco E, Concepcion W.
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [Abstract] [Full Text] [Related]

  • 6. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ.
    Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
    [Abstract] [Full Text] [Related]

  • 7. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
    Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, Madariaga J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A.
    Transplant Proc; 2005 Mar; 37(2):1217-9. PubMed ID: 15848674
    [Abstract] [Full Text] [Related]

  • 8. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study.
    Lladó L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T, Torras J, Garcia-Gil A, Gonzalez-Pinto I, Castellote J, Baliellas C, Fabregat J, Rafecas A, Thosin Study Group.
    J Hepatol; 2006 Apr; 44(4):710-6. PubMed ID: 16487622
    [Abstract] [Full Text] [Related]

  • 9. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
    [Abstract] [Full Text] [Related]

  • 10. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 11. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S.
    Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
    [Abstract] [Full Text] [Related]

  • 12. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab.
    Andrade-Sierra J, Rojas-Campos E, Cardona-Muñoz E, Evangelista-Carrillo LA, Puentes-Camacho A, Lugo-López O, Gómez B, Valdespino C, Cerrillos I, Medina-Pérez M, Jalomo B, Nieves JJ, Sandoval M, Ramos-Solano F, Monteón-Ramos F, Cueto-Manzano AM.
    Nefrologia; 2014 Aug; 34(2):216-22. PubMed ID: 24658197
    [Abstract] [Full Text] [Related]

  • 13. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, Shiffman ML, Luketic VA, Contos MJ, Mills AS, Ferreira-Gonzalez A, Posner MP.
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [Abstract] [Full Text] [Related]

  • 14. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 15. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 16. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
    Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG.
    Liver Transpl; 2011 Dec 20; 17(12):1394-403. PubMed ID: 21850690
    [Abstract] [Full Text] [Related]

  • 17. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
    Gentile G, Somma C, Gennarini A, Mastroluca D, Rota G, Lacanna F, Locatelli B, Remuzzi G, Ruggenenti P.
    Am J Nephrol; 2015 Dec 20; 41(1):16-27. PubMed ID: 25612603
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.
    Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A.
    Transplantation; 2007 Oct 15; 84(7):829-35. PubMed ID: 17984834
    [Abstract] [Full Text] [Related]

  • 19. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.
    Gavela Martínez E, Avila Bernabeu AI, Sancho Calabuig A, Beltrán Catalán S, Escudero Quesada V, Pallardó Mateu LM.
    Transplant Proc; 2009 Oct 15; 41(6):2337-8. PubMed ID: 19715913
    [Abstract] [Full Text] [Related]

  • 20. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy.
    Vessal G, Wiland AM, Philosophe B, Fink JC, Weir MR, Klassen DK.
    Clin Transplant; 2007 Oct 15; 21(4):491-7. PubMed ID: 17645708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.